If It's Worth Doing, It's Worth Doing Right (FDA, That Means You)

A Wall Street Journal article reports on Harvard professor Daniel Carpenter, who is defending research indicating that the US FDA made "overly hasty approval decisions on medicines," now that FDA has criticized the research as flawed. Evidently, the original study did have mistakes -- but Carpenter says that coincides with errors in the FDA's own records. He says that "after he made necessary corrections, his original finding still held: Drugs that the FDA has approved soon before a regulatory deadline have been more likely to develop severe safety problems later on," according to the article.